DNAJC5 and malaria: We developed vaccines targeting the epitopes of two anti-Pf circumsporozoite protein (CSP) monoclonal antibodies (mAbs), called CIS43 and L9 [27,28], which are amongst the most potent mAbs at providing protection from experimental malaria challenge in mouse models [29,30].